Navigation Links
NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
Date:9/9/2013

CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH).  Subsequent funding, to be released on demonstration of superiority, will be used for later stage development.  The NIH award represents a major step toward commercialization of the Company's orphan disease therapy platform.

(Logo: http://photos.prnewswire.com/prnh/20130909/DC73243LOGO )

The grant follows strong evidence from recent studies that its lead candidate will block intra- and extra-vascular hemolysis, both of which must be controlled in order to gain advantages over eculizumab. These studies indicate that NovelMed's lead candidate could have a superior efficacy, safety and dosage profile relative to eculizumab.  The project will compare the two therapies under various experimental conditions.

"As a small business we applaud the support of the NIH in transitioning promising technologies from the laboratory to the clinic. We are honored that the scientific peer-review process at the NIH has repeatedly deemed our developmental concepts worthy of continued support as we advance the development of life-changing products," stated Rekha Bansal, Ph.D., Founder and Chief Executive Officer of NovelMed.

About PNH

PNH is a rare and life-threatening blood disorder where the immune system attacks red blood cells resulting in significant disease outcomes including red blood cell destruction and long-term anemia. Current treatment options are limited and only control cell destruction via the intravascular pathway. Despite staggering success of the current complement inhibitor being marketed, some patients continue to remain anemic due to the second newly-discovered pathway for red blood cell destruction also known as "extravascular hemolysis". NovelMed's leading drug candidate prevents red blood cell destruction via both pathways and therefore is expected to provide significant benefit in the total control of anemia.

About NovelMed

NovelMed Therapeutics, Inc., a privately-held biotech located in Cleveland, Ohio, is developing transformative treatments for orphan and non-orphan disease conditions.  The company has developed a portfolio of antibodies targeted for the treatments of complement-mediated inflammatory and hemolytic disorders including paroxysmal nocturnal Hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (Dry & Wet AMD), arthritis (RA & OA), and cardiovascular diseases.  NovelMed's drug candidates are differentiated by their unique mechanism(s) of action that are expected to deliver therapies with superior efficacy, safety and dosage profiles. The company is currently looking for strategic partners for clinical trials and commercialization of its therapeutic drugs.

Similar drug discovery is being pursued by a few companies including Roche/Genentech and Novartis, which are both pursuing AMD therapies, and Alexion which is currently marketing Soliris (eculizumab), an FDA approved antibody-based therapy.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this press release was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number R44HL115909.  


'/>"/>
SOURCE NovelMed
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. QBC Diagnostics Awarded GSA Contract
3. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
4. Northwest Bio Awarded $5.5 Million German Government Grant
5. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
6. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
7. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
8. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
9. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
10. Sorrento Therapeutics Awarded Third Phase I STTR Grant
11. Texas A&M System Awarded National Center for Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):